Toll-like receptor-positive cells and recognition of pathogens: How human myeloid dendritic cells respond to In vitro infection with Leishmania infantum

Current Pharmaceutical Design

Volumn 12, Issue 32, 2006, Pages 4255-4262

  Pepe, Maria ^a   Altamura, Maria ^a   Spinelli, Rosa ^a   Calvello, Rosa ^a   Saccia, Matteo ^a   Cavallo, Pasqua ^a   Covelli, Vito ^b   Jirillo, Emilio ^a,c,d   Brandonisio, Olga ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Polyclinic   (Italy)

^c NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^d POLICLINICO   (Italy)

Author keywords

IL 12; Interferon; Leishmania; Lymphocytes; Phagocytosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P70; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ; TOLL LIKE RECEPTOR;

BONE MARROW; CD4+ T LYMPHOCYTE; CELL POLARITY; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DATA ANALYSIS; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOTHERAPY; IN VITRO STUDY; INCUBATION TIME; LEISHMANIA INFANTUM; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROMASTIGOTE; REVIEW; SIGNAL TRANSDUCTION; SUPERNATANT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; LEISHMANIA INFANTUM; MACROPHAGES; PHAGOCYTOSIS; TH1 CELLS; TIME FACTORS; TOLL-LIKE RECEPTORS;

EID: 33750544925     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778743556     Document Type: Review

References (66)

1. Mazzoni A, Segal DM. Controlling the Toll road to dendritic cell polarization. J Leukoc Biol 2004; 75: 721-30.
2. Netea MG, van der Graaf C, van der Meer JWM, Kullberg BJ. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol 2004; 75: 749-55.
3. Smits HH, de Jong EC, Wierenga EA, Kapsenberg ML. Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol 2005; 26: 123-9.
4. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnkay D, Mahnke K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann NY Acad Sci 2003; 987: 15-25.
5. Kaisho T, Akira S. Dendritic cell function in Toll-like receptor and MyD88-knockout mice. Trends Immunol 2001; 22: 78-83.
6. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-69.
7. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
8. Pulendran B, Kumar P, Cutner CW, Mohamadzadeh M, van Dyke T, Banchereau J. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 2001; 167: 5067-76.
9. Cella M, Saho M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999; 189: 821-9.
10. Agrawal S, Agrawal A, Soughty B, Gerwitz A, Blenis J, van Dyke T, et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protean kinase and c-Fos. J Immunol 2003; 171: 4984-9.
11. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajma K, Vehira K, et al. Interferon-α and interleukin 12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195: 1507-12.
12. Krug A, Towarowski A, Britsch S, Tothenfusser S, Hornung U, Bals R, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31: 3026-7.
13. Manickasingham SP, Edwards AD, Schulz O, Reis e Sousa C. The ability of murine dendritic cell subset to direct T helper cell differentiation is dependent on microbial signals. Eur J Immunol 2003; 33: 101-7.
14. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276: 37692-9.
15. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000; 164: 4507-12.
16. Mailliard RB, Son YI, Redlanger R, Coates PT, Giermasz A, Morel PA, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction on NK cell helper function. J Immunol 2003; 171: 2365-73.
17. Wilson ME, Jeronimo SM, Pearson RD. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 2005; 38: 147-60.
18. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
19. http://www.who.int/tdr/diseases/leish/diseaseinfo.htm
20. Ashford RW. The leishmaniases as emerging and reemerging zoonoses. Int J Parasitol 2000; 30: 269-81.
21. Mauel J. Vaccination against Leishmania infections. Curr Drug Targets Immune Endocr Metabol Disord 2002; 2: 201-26.
22. Brandonisio O, Panaro MA, Sisto M, Acquafredda A, Fumarola L, Leogrande D. Interactions between Leishmania parasites and host cells. Parassitologia 2000; 42: 183-90.
23. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 2004; 16: 21-5.
24. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3: 984-93.
25. Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YAW, Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be mediated by molecularly defined antigens. J Immunol 2003; 170: 3171-9.
26. Brandonisio O, Spinelli R, Pepe M. Dendritic cells in Leishmania infection. Microbes Infect 2004; 6: 1402-9.
27. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-18.
28. Sher A, Pearce E, Kaye P. Shaping the immune response to parasites: role of dendritic cells. Curr Opin Immunol 2003; 15: 421-9.
29. Moll H, Flohé S, Rollinghoff M. Dendritic cells in Leishmania major-immune mice harbour persistent parasites and mediate an antigen-specific T cell immune response. Eur J Immunol 1995; 25: 693-9.
30. Baldwin T, Henri S, Curtis J, O'Keeffe M, Vremec D, Shortman K, et al. Dendritic cell populations in Leishmania major-infected skin and draining lymph nodes. Infect Immun 2004; 72: 1991-2001.
31. Ritter U, Meissner A, Scheidig C, Korner H. CD8 alpha- and Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-presenting cells in leishmaniasis. Eur J Immunol 2004; 34: 1542-50.
32. von Stebut E, Belkaid Y, Jakob T, Sacks DL, Udey MC. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med 1998; 188: 1547-52.
33. Konecny P, Stagg AJ, Jebbari H, English N, Davidson RN, Knight SC. Murine dendritic cells internalize Leishmania major promastigotes, produce IL-12 p40 and stimulate primary T cell proliferation in vitro. Eur J Immunol 1999; 29: 1803-11.
34. Prina E, Abdi SZ, Lebastard M, Perret E, Winter N, Antoine JC. Dendritic cells as host cells for the promastigote and amastigote stages of Leishmania amazonensis: the role of opsonins in parasite uptake and dendritic cell maturation. J Cell Sci 2004; 117: 315-25.
35. Henri S, Curtis J, Hochrein H, Vremec D, Shortman K, Handman E. Hierarchy of susceptibility of dendritic cell subsets to infection by Leishmania major: inverse relationship to interleukin-12 production. Infect Immun 2002; 70: 3874-80.
36. Carrera L, Gazzinelli RT, Badolato R, Hieny S, Muller W, Kuhn R, et al. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 1996; 183: 515-26.
37. + T cells during initiation of infection. J Exp Med 1994; 179: 447-56.
38. Sartori A, Oliveira MA, Scott P, Trinchieri G. Metacyclogenesis modulates the ability of Leishmania promastigotes to induce IL-12 production in human mononuclear cells. J Immunol 1997; 159: 2849-57.
39. Oliveira MA, Tadokoro CE, Lima GM, Mosca T, Vieira LQ, Leenen PJ, et al. Macrophages at intermediate stage of maturation produce high levels of IL-12 p40 upon stimulation with Leishmania. Microbes Infect 2005; 7:213-23.
40. Chen G, Darrah PA, Mosser DM. Vaccination against the intracellular pathogens Leishmania major and L. amazonensis by directing CD40 ligand to macrophages. Infect Immun 2001; 69: 3255-63.
41. Marovich MA, McDowell MA, Thomas EK, Nutman TB. IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process. J Immunol 2000; 164: 5858-65.
42. McDowell MA, Marovich M, Lira R, Braun M, Sacks D. Leishmania priming of human dendritic cells for CD40 ligand-induced interleukin-12p70 secretion is strain and species dependent. Infect Immun 2002; 70: 3994-4001.
43. Bennett CL, Misslitz A, Colledge L, Aebischer T, Blackburn CC. Silent infection of bone marrow-derived dendritic cells by Leishmania mexicana amastigotes. Eur J Immunol 2001; 31: 876-83.
44. Turco SJ, Spath GF, Beverley SM. Is lipophosphoglycan a virulence factor? A surprising diversity between Leishmania species. Trends Parasitol 2001; 17: 223-6.
45. Constant SL, Lee KS, Bottomly K. Site of antigen delivery can influence T cell priming: pulmonary environment promotes preferentially Th2-type differentiation. Eur J Immunol 2000; 30: 840-7.
46. Constant SL, Brogdon JL, Piggott DA, Herrick LA, Visintin I, Ruddle NH, et al. Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. J Clin Invest 2002; 110: 1441-8.
47. Dodge IL, Carr MW, Cernada SM, Brenner MB. IL-6 production by pulmonary dendritic cells impedes Th1 immune responses. J Immunol 2003; 170: 4457-64.
48. Engwerda CR, Ato M, Kaye PM. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol 2004; 20: 524-30.
49. Engwerda CR, Kaye PM. Organ-specific immune responses associated with infectious diseases. Immunol Today 2000; 21: 73-78.
50. Sporri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 2005; 6: 163-70.
51. Goldstein DR. Toll-like receptors and other links between innate and acquired alloimmunity. Curr Opin Immunol 2004; 16: 538-44.
52. de Trez C, Brait M, Leo O, Aebischer T, Torrentera FA, Carlier Y, et al. Myd88-dependent in vivo maturation of splenic dendritic cells induced by Leishmania donovani and other Leishmania species. Infect Immun 2004; 72: 824-32.
53. de Veer MJ, Curtis JM, Baldwin TM, Di Donato JA, Sexton A, McConville MJ, et al. MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol 2003; 33: 2822-31.
54. Aebischer T, Bennett CL, Pelizzola M, Vizzardelli C, Pavelka N, Urbano M, et al. A critical role for lipophosphoglycan in proinflammatory responses of dendritic cells to Leishmania mexicana. Eur J Immunol 2005; 35: 476-86.
55. Kropf P, Freudenberg MA, Modolell M, Price HP, Herath S, Antoniazi S, et al. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun 2004; 72: 1920-8.
56. Kropf P, Freudenberg N, Kalis C, Modolell M, Herath S, Galanos C, et al. Infection of C57BL/10ScCr and C57BL/10ScNCr mice with Leishmania major reveals a role for Toll-like receptor 4 in the control of parasite replication. J Leukoc Biol 2004; 76: 48-57.
57. Moll H. Antigen delivery by dendritic cells. Int J Med Microbiol 2004; 294: 337-44.
58. Feili-Hariri M, Falkner DH, Morel PA. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol 2005; 78: 656-64.
59. + regulatory T cells control Leishmania major persistance and immunity. Nature 2002; 420: 502-7.
60. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, et al. The role of interleukin (IL)-10 in the persistance of Leishmania major in the skin after healing and the therapeutic potential of anti IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194: 1497-506.
61. Svensson M, Maroof A, Ato M, Kaye PM. Stromal cells direct local differentiation of regulatory dendritic cells. Immunity 2004; 21: 805-16.
62. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296-306.
63. McIlroy D, Tanguy-Royer S, Le Meur N, Guisle I, Royer PJ, Leger J, et al. Profiling dendritic cell maturation with dedicated microarrays. J Leukoc Biol 2005; 78: 794-803.
64. Altmeyer R. Virus attachment and entry offer numerous targets for antiviral therapy. Curr Pharm Des 2004; 10(30): 3701-12.
65. Cortes-Selva F, Jimenez IA, Munoz-Martinez F, Campillo M, Bazzocchi IL, Pardo L, et al. Dihydro-beta-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania. Curr Pharm Des 2005; 11(24): 3125-39.
66. Foster AE, Forrester K, Li YC, Gottlieb DJ. Ex-vivo uses and applications of cytokines for adoptive immunotherapy in cancer. Curr Pharm Des 2004; 10(11): 1207-20.